|
|
Binance |
|
|
Coinbase |
|
|
KUCOIN |
|
|
AscendEX (Formally BitMax) |
By Trader Edge at 2026-10-03 11:34
Sentiment: Positive
TLDR Wolfe Research upgraded both Biogen and AbbVie to Outperform, setting a $300 price target for each Biogen’s late-stage pipeline drugs litifilimab and felzartamab were flagged as key growth assets AbbVie’s patent on Rinvoq was pushed out to 2037, removing a major near-term patent cliff concern AbbVie posted Q2 revenue of $16.99 billion, up 10.2% [...] The post Biogen and AbbVie Get Double Upgrades From Wolfe Research. Are They a Buy Now? appeared first on CoinCentral. Continue reading...
Categories: Stocks
Tags: #Stocks
Source Coin Central